International Journal of Scientific Research and Engineering Development-– Volume 8 Issue 1, Jan-Feb 2025
Available at www.ijsred.com

RESEARCH ARTICLE OPEN ACCESS

Myasthenia Gravis: A Comprehensive Review of Immune Dysregulation and Etiological Mechanisms

Donthu. Susmitha*, Shaik Fahad, MD. Sahil Chaudhary, Rijwan Ahmad, MD. K.M. Azeem
Nimra college of Pharmacy, Jupudi, Ibrahimpatnam, NTR-AP-521456
Email: sushmitha.ijjagani99@gmail.com

ABSTRACT
Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by fluctuating muscle weakness and fatigue, primarily affecting voluntary muscles. It results from an autoimmune response where antibodies target acetylcholine receptors at the neuromuscular junction, impairing nerve-muscle communication. This leads to symptoms such as ptosis, diplopia, dysphagia, and generalized muscle weakness. Diagnosis involves clinical evaluation, serological tests for specific antibodies, and electrophysiological studies. Treatment strategies include acetylcholinesterase inhibitors, immunosuppressive therapy, plasmapheresis, and thymectomy. Although MG is a lifelong condition, advancements in medical management have significantly improved patient outcomes and quality of life. This review explores the pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic interventions for Myasthenia Gravis, highlighting recent advancements and challenges in its management.

Keywords: Myasthenia Gravis, Autoimmune Disorder, Neuromuscular Junction, Acetylcholine Receptors, Muscle Weakness, Ptosis, Diplopia, Dysphagia, Immunosuppressive Therapy, Thymectomy, Acetylcholinesterase Inhibitors, Neuromuscular Transmission, Autoantibodies, Myasthenic Crisis.

INTRODUCTION:

Myasthenia gravis (MG) is an antibody-mediated autoimmune disorder that impairs the function of the neuromuscular junction, leading to fluctuating muscle weakness. This weakness commonly affects the ocular, facial, bulbar, limb, and respiratory muscles. The global prevalence of MG is estimated to range between 70–300 cases per million people. Uncontrolled disease can result in significant disability, recurrent hospitalizations, and an estimated mortality rate of about 2% **(DeHart-McCoyle M et al.,2023)**. Despite its potential severity, MG is largely a treatable condition, and early diagnosis and appropriate management can prevent considerable morbidity and mortality.1,2

MG is a heterogeneous disease in terms of its phenotype and pathogenesis. Clinical manifestations vary from isolated ocular symptoms to severe generalized weakness involving multiple muscle groups. The onset of MG can occur at any age, but it peaks in younger adult women and older men (**Ekor, M et al,2014).** 3,6

The earliest recorded case of myasthenia gravis (MG) may have been that of Chief Opechancanough, a Native American leader who died in 1664. According to Virginian chroniclers, "Excessive fatigue wrecked his constitution, his flesh deteriorated, his sinews lost strength, and his eyelids became so heavy that attendants had to lift them for him to see. Unable to walk, he directed from the litter on which his people carried him." In 1672, Thomas Willis, an English physician, documented a patient exhibiting "fatiguable weakness" in the limbs and bulbar muscles, characteristic of MG.8

In the late 19th century, the first modern accounts of patients with symptoms resembling MG were published. The term "myasthenia gravis" was derived by combining the Greek word "myasthenia," meaning muscle weakness, with the Latin term "gravis," signifying severe.11 Efforts to develop effective treatments for MG began in the 1930s. A breakthrough occurred in 1934 when Mary Walker observed similarities between MG symptoms and those of curare poisoning, which was treated with the cholinesterase inhibitor physostigmine. She demonstrated that physostigmine significantly alleviated myasthenic symptoms, leading to the

incorporation of anticholinesterase medications in MG management.10

Thymus abnormalities were first recognized in MG patients during the late 19th century. In 1937, Alfred Blalock performed a thymectomy on a young woman with MG, who showed improvement after surgery. Blalock later reported additional cases of MG patients benefiting from thymus removal, establishing thymectomy as a viable treatment option for the disease.12

PATHOPHYSIOLOGY:

MG is primarily caused by autoantibodies that target components of the neuromuscular junction:

Acetylcholine receptor antibodies: The most common type, present in about 80-85% of generalized MG cases. these antibodies block, alter, or destroy aChrs, impairing neuromuscular transmission.7,9

Muscle-specific kinase (MuSk) antibodies: Found in 10-15% of MG patients, particularly those without achr antibodies. MuSk antibodies disrupt clustering of aChrs, leading to impaired muscle activation.13

LRP4 antibodies: Less commonly associated but also implicated in MG pathogenesis.13

The thymus gland is believed to play a critical role in the disease's autoimmune mechanism. many MG patients exhibit thymic abnormalities, such as hyperplasia or thymoma, which may trigger the production of pathogenic autoantibodies.14

CLINICAL MANIFESTATIONS:

MG is characterized by fluctuating weakness in voluntary muscles, typically worsening with activity and improving with rest. Common symptoms include:

Ocular symptoms: Ptosis (drooping of eyelids) and diplopia (double vision) are often the initial manifestations.5

Bulbar symptoms: Dysphagia (difficulty swallowing), dysarthria (slurred speech), and chewing fatigue.5

Limb and axial muscle weakness: Involvement of neck and limb muscles, leading to difficulty in lifting objects or maintaining posture.5

Respiratory muscle weakness: In severe cases, respiratory failure can occur, leading to a myasthenic crisis, which is a medical emergency.5

DIAGNOSTIC APPROACHES:

Clinical examination: Observation of muscle weakness that worsens with activity and improves with rest.5

Serological tests: Detection of autoantibodies against aChr, MuSk, or LRP4.5

Electrophysiological studies:

Repetitive nerve stimulation (RNS): Shows a decremental response in muscle action potentials.15

Single-fiber electromyography (SFEMG): Most sensitive test, detecting abnormalities in neuromuscular transmission.15

Pharmacological test: Edrophonium test (Tensilon test) temporarily improves muscle strength by inhibiting acetylcholinesterase, thus increasing acetylcholine availability.15

Imaging studies: CT or MRI of the chest to detect thymic abnormalities, such as thymoma.15

TREATMENT STRATEGIES:

Symptomatic management:

Acetylcholinesterase inhibitors: Pyridostigmine is the first-line drug that enhances neuromuscular transmission.7,9

Immunosuppressive therapy:

Corticosteroids: Prednisone is commonly used to reduce autoimmune activity.14

Non-steroidal immunosuppressants: Azathioprine, mycophenolate mofetil, and cyclosporine.14

Biologic therapies: Rituximab and eculizumab are used in refractory cases.14

Rapid immunomodulatory therapies:

Plasmapheresis: Removes circulating antibodies, providing rapid improvement during myasthenic crises.4

Intravenous immunoglobulin (IVIG): Modulates immune response and provides short-term relief.4

Surgical intervention:

Thymectomy: Surgical removal of the thymus gland is particularly beneficial for patients with thymoma or generalized mg. studies indicate improved clinical outcomes and reduced medication dependence post-thymectomy.4

PROGNOSIS AND QUALITY OF LIFE:

The prognosis for MG has significantly improved due to advancements in diagnosis and treatment. with appropriate management, most patients achieve good control over their symptoms and maintain a normal or near-normal quality of life. however, disease severity and response to treatment vary among individuals. regular follow-up and personalized therapeutic adjustments are crucial for optimal disease management.3

RECENT ADVANCES AND FUTURE DIRECTIONS:

Targeted therapies: Research on complement inhibitors like eculizumab and fcrn antagonists shows promise in reducing pathogenic antibodies.5

Gene therapy and monoclonal antibodies: Emerging therapeutic strategies aim at specific immune targets to provide long-term remission.5

Biomarkers for disease monitoring: Efforts are ongoing to identify reliable biomarkers for disease activity and treatment response.6

CONCLUSION:

Myasthenia gravis is a complex autoimmune neuromuscular disorder with significant clinical variability. advances in understanding its immunopathogenesis have paved the way for targeted therapies, enhancing patient outcomes. while current treatments effectively manage symptoms and improve quality of life, challenges remain in achieving long-term remission and preventing disease progression. ongoing research and clinical trials hold promise for more precise and personalized therapeutic approaches, offering hope for better management and potential cure in the future.

REFERENCES:

1. Chen Z, Zuo J, Zou J, Sun Y, Liu W, Lai Y, Zhong B, Su C, Tan M, Luo H. Cellular immunity following video-assisted thoracoscopic and open resection for non-thymomatous myasthenia gravis. Eur J Cardiothorac Surg. 2014 Apr;45(4):646-51. doi: 10.1093/ejcts/ezt443. Epub 2013 Sep 4. PMID: 24005161.
2. Shimkevich LL, Rudneva VG, Sapin SM, Marchuk AI, Golovteev VV. Trombotsitarnye narusheniia pri generalizovannoĭ miastenii i ikh korrektsiia s pomo'shchiu plazmafereza i vvedeniia anti- syvorotok k immunoglobulinam [Thrombocytic diseases in generalized myasthenia gravis and their correction by using plasmapheresis and administration of anti-immunoglobulin antisera]. Zh Nevropatol Psikhiatr Im S S Korsakova. 1989;89(11):47-50. Russian. PMID: 2624050.
3. Yaru Lu, Qian Ma, Lu Yu, Xiaoxi Liu, Pei Chen, Weibin Liu, Circulating CD45RA−Foxp3++ Treg cells serve as a biomarker for predicting minimal clinical manifestations status of myasthenia gravis,Life Sciences, Volume 358,2024,123162,ISSN 0024-3205, https://doi.org/10.1016/j.lfs.2024.123162.
4. Jing S, Lu J, Song J, Luo S, Zhou L, Quan C, Xi J, Zhao C. Effect of low-dose rituximab treatment on T- and B-cell lymphocyte imbalance in refractory myasthenia gravis. J Neuroimmunol. 2019 Jul 15;332:216-223. doi: 10.1016/j.jneuroim.2019.05.004. Epub 2019 May 9. PMID: 31100692.
5. Ullah U, Iftikhar S, Javed MA. Relationship between Low and High Anti-acetylcholine Receptor Antibody Titers and Clinical Severity in Myasthenia Gravis. J Coll Physicians Surg Pak. 2021 Aug;31(8):965-968. doi: 10.29271/jcpsp.2021.08.965. PMID: 34320716.
6. ulok K. Mukherjee, Venkatesan Kumar, Mainak Mal, Peter J. Houghton,Acetylcholinesterase inhibitors from plants ,Phytomedicine, Volume 14, Issue 4,2007,Pages 289-300, ISSN 0944-7113,https://doi.org/10.1016/j.phymed.2007.02.002.
7. Vincent A, Scadding GK, Thomas HC, Newsom-Davis J. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet. 1978 Feb 11;1(8059):305-7. doi: 10.1016/s0140-6736(78)90073-9. PMID: 75339.
8. Basta M, Illa I, Dalakas MC. Increased in vitro uptake of the complement C3b in the serum of patients with Guillain-Barré syndrome, myasthenia gravis and dermatomyositis. J Neuroimmunol. 1996 Dec;71(1-2):227-9. doi: 10.1016/s0165-5728(96)00133-6. PMID: 8982124.
9. Feng X, Wang X, Liu Y, Di X. Linarin Inhibits the Acetylcholinesterase Activity In-vitro and

Ex-vivo. Iran J Pharm Res. 2015 Summer;14(3):949-54. PMID: 26330885; PMCID: PMC4518125.

10. Abramsky O, Brenner T, Lisak RP, Zeidman A, Beyth Y. Significance in neonatal myasthenia gravis of inhibitory effect of amniotic fluid on binding of antibodies to acetylcholine receptor. Lancet. 1979 Dec 22-29;2(8156-8157):1333-5. doi: 10.1016/s0140-6736(79)92815-0. PMID: 92675.
11. Shumei Y, Yi L, Huanyu M, Zhibin L, Wanlin J, Liqun X, Huan Y. IL-2 gene polymorphisms affect tacrolimus response in myasthenia gravis. Eur J Clin Pharmacol. 2019 Jun;75(6):795-800. doi: 10.1007/s00228-019-02642-z. Epub 2019 Feb 7. PMID: 30729267.
12. Lazaridis K, Fernandez-Santoscoy M, Baltatzidou V, Andersson JO, Christison R, Grünberg J, Tzartos S, Löwenadler B, Fribert C. A Recombinant Acetylcholine Receptor α1 Subunit Extracellular Domain Is a Promising New Drug Candidate for Treatment Of Myasthenia Gravis. Front Immunol. 2022 Jun 3;13:809106. doi: 10.3389/fimmu.2022.809106. PMID: 35720339; PMCID: PMC9204200.
13. Wu DP, Lin TY, Lv JY, Chen WY, Bai LR, Zhou Y, Huang JL, Zhong ZG. Cestrum nocturnum Flower Extracts Attenuate Proliferation and Induce Apoptosis in Malignant Cells through Inducing DNA Damage and Inhibiting Topoisomerase II Activity. Evid Based Complement Alternat Med. 2017;2017:1456786. doi: 10.1155/2017/1456786. Epub 2017 Jan 31. PMID: 28250789; PMCID: PMC5307125.
14. Bano, N., Fakhrah, S., Nayak, S. P., Bag, S. K., & Mohanty, C. S. (2022). Identification of miRNA and their target genes in Cestrum nocturnum L. and Cestrum diurnum L. in stress responses. Physiology and Molecular Biology of Plants, 28(1), 31-49.
15. Keshari AK, Srivastava R, Singh P, Yadav VB, Nath G. Antioxidant and antibacterial activity of silver nanoparticles synthesized by Cestrum nocturnum. J Ayurveda Integr Med. 2020 Jan-Mar;11(1):37-44. doi: 10.1016/j.jaim.2017.11.003. Epub 2018 Aug 16. PMID: 30120058; PMCID: PMC7125370.

